ShangPharma Corporation, the second-largest Chinese pharmaceutical/biotechnology R&D outsourcing firm, raised $87 million by offering 5.8 million ADSs at $15, within the range of $14.50-$16.50. ShangPharma Corporation plans to list on the NYSE under the symbol SHP. Citi and J.P. Morgan acted as lead managers on the deal.
